Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium

dogruel, fatma; GÜNAY CANPOLAT, DILEK; rıhtım, tuğba; koker, Mustafa Yavuz; Şimşek, Sevil; Yilmaz, Insu

doi:10.14744/etd.2022.80633

Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium

Fatma DOĞRUEL, (Ağız ve Diş Sağlığı Bölümü Maksillofasiyal cerrahi, Erciyes Üniversitesi Tıp Fakültesi Diş Hekimliği, Kayseri, Türkiye)

Dilek GÜNAY CANPOLAT, (Ağız ve Diş Sağlığı Bölümü Maksillofasiyal cerrahi, Erciyes Üniversitesi Tıp Fakültesi Diş Hekimliği, Kayseri, Türkiye)

Sevil Şimşek, (İmmünoloji Bölümü, Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Türkiye)

Tuğba RIHTIM, (İmmünoloji Bölümü, Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Türkiye)

Mustafa Yavuz KÖKER, (İmmünoloji Bölümü, Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Türkiye)

İnsu YILMAZ (İmmünoloji ve Alerji Bölümü, Göğüs Hastalıkları Bölümü, Erciyes Üniversitesi Tıp Fakültesi, Kayseri, Türkiye)

Erciyes Medical Journal

5 0

Yıl: 2023 Cilt: 45 Sayı: 1 Sayfa Aralığı: 25 - 31 Metin Dili: İngilizce DOI: 10.14744/etd.2022.80633 İndeks Tarihi: 28-05-2023

Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium

Öz:

Objective: Neuromuscular blocking agents (NMBA) are commonly used in general anesthetic applications, and are respon- sible for more than half of all anaphylactic reactions during general anesthesia. The aim of this study is to investigate the contribution of BasophilActivation Test (BAT) to the diagnosis in patients who developed an immediate drug hypersensitivity reaction due to rocuronium. Materials and Methods: The study included 10 patients who developed urticaria and/or angioedema following rocuroni- um administration during anesthesia. Hypersensitivity to rocuronium was assesed with BAT including CD63 and CD203c expression analysis of blood samples by flow cytometry at least one month after the reactions. Results: All patients were found positive for CD63 expression at the drug dilutions of 0.01 and 0.1 mg/ml, while nine (90%) patients were positive at the drug dose of 1 mg/ml. When assessing the CD203% expression at different drug dilutions, seven (70%) patients were found to be positive at the drug dilutions of 0.01 and 0.1 mg/ml, while eight (80%) were positive at the drug dose of 1 mg/ml. Conclusion: This study has demonstrated that BAT can be used for diagnostic purposes in immediate drug hypersensitivity reactions to NMBA like rocuronium. The present study, to the best of our knowledge, is the first to assess the diagnostic significance of BAT in immediate drug hypersensitivity reactions caused by rocuronium in our country.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Matthey P, Wang P, Finegan BA, Donnelly M. Rocuronium anaphy- laxis and multiple neuromuscular blocking drug sensitivities. Can J An- aesth 2000; 47(9): 890–3.
2. Mertes PM, Laxenaire MC, Alla F; Groupe d’Etudes des Réactions Anaphylactoïdes Peranesthésiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anes- thesiology 2003; 99(3): 536–45.
3. Rose M, Fisher M. Rocuronium: high risk for anaphylaxis?. Br J An- aesth. 2001; 86(5): 678–82.
4. Kalangara J, Vanijcharoenkarn K, Lynde GC, McIntosh N, Kuruvilla M. Approach to perioperative anaphylaxis in 2020: Updates in diag- nosis and management. Curr Allergy Asthma Rep 2021; 21(1): 4.
5. Ebo DG, Sainte-Laudy J, Bridts CH, Mertens CH, Hagendorens MM, Schuerwegh AJ, et al. Flow-assisted allergy diagnosis: current applica- tions and future perspectives. Allergy 2006; 61(9): 1028–39.
6. Dhonneur G, Combes X, Chassard D, Merle JC. Skin sensitivity to ro- curonium and vecuronium: a randomized controlled prick-testing study in healthy volunteers. Anesth Analg 2004; 98(4): 986–9.
7. Tamayo E, Rodríguez-Ceron G, Gómez-Herreras JI, Fernández A, Castro- deza J, Alvarez FJ. Prick-test evaluation to anaesthetics in patients attend- ing a general allergy clinic. Eur J Anaesthesiol 2006; 23(12): 1031–6.
8. Özdemir Ö, Karavaizoğlu Ç. Utilization of flow cytometry in immu- nologic and allergic diseases. Asthma Allergy Immunol 2016; 14(3): 117–28.
9. Özdemir, Ö. Basophil Activation in Immediate Drug Hypersensi- tivity Reactions and Basophil Activation Test (BAT). Istanbul Med J 2017;18:109–13.
10. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcy- tometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005; 136(1): 58–72.
11. Boumiza R, Debard AL, Monneret G. The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy 2005; 3: 9.
12. Monneret G, Benoit Y, Debard AL, Gutowski MC, Topenot I, Bien- venu J. Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. Clin Immunol 2002; 102(2): 192–9.
13. Veien M, Szlam F, Holden JT, Yamaguchi K, Denson DD, Levy JH. Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells. Anesthesiology 2000; 92(4): 1074–81.
14. Reid MS, Imray JM, Noble D W. Anesthesic allergy and prospective ra- dioallergo sorbent testing. Monographs in Allergy 1992; 30:162–73.
15. Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Allergy 2006; 61(8): 935–9.
16. Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: Mecha- nisms and considerations for use in clinical trials and clinical practice. Allergy 2021; 76: 2420–32.
17. van der Poorten MM, Walschot M, Faber M, Elst J, Van Gasse AL, De Puysseleyr L, et al. Reliability of early and late testing for suspect- ed perioperative hypersensitivity. J Allergy Clin Immunol Pract 2022; 10(4): 1057–62.e2.
18. Hagau N, Gherman-Ionica N, Sfichi M, Petrisor C. Threshold for baso- phil activation test positivity in neuromuscular blocking agents hyper- sensitivity reactions. Allergy Asthma Clin Immunol 2013; 9(1): 42.
19. Dewachter P, Chollet-Martin S, Mouton-Faivre C, de Chaisemartin L, Nicaise-Roland P. Comparison of basophil activation test and skin testing performances in NMBA Allergy. J Allergy Clin Immunol Pract 2018; 6(5): 1681–9.
20. Abuaf N, Rajoely B, Ghazouani E, Levy DA, Pecquet C, Chabane H, et al. Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy. J Allergy Clin Immunol 1999; 104(2 Pt 1): 411–8.
21. Li J, Best OG, Rose MA, Green SL, Fulton RB, Fernando SL. Integrat- ing basophil activation tests into evaluation of perioperative anaphy- laxis to neuromuscular blocking agents. Br J Anaesth 2019; 123(1): e135–43.
22. Kvedariene V, Kamey S, Ryckwaert Y, Rongier M, Bousquet J, Demo- ly P, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. Allergy 2006; 61(3): 311–5.
23. Li J, Best OG, Rose MA, Green SL, Fulton RB, Capon MJ, et al. As- sessing cross-reactivity to neuromuscular blocking agents by skin and basophil activation tests in patients with neuromuscular blocking agent anaphylaxis. Br J Anaesth 2019; 123(1): e144–50.

APA	dogruel f, GÜNAY CANPOLAT D, Şimşek S, rıhtım t, koker M, Yilmaz I (2023). Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. , 25 - 31. 10.14744/etd.2022.80633
Chicago	dogruel fatma,GÜNAY CANPOLAT DILEK,Şimşek Sevil,rıhtım tuğba,koker Mustafa Yavuz,Yilmaz Insu Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. (2023): 25 - 31. 10.14744/etd.2022.80633
MLA	dogruel fatma,GÜNAY CANPOLAT DILEK,Şimşek Sevil,rıhtım tuğba,koker Mustafa Yavuz,Yilmaz Insu Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. , 2023, ss.25 - 31. 10.14744/etd.2022.80633
AMA	dogruel f,GÜNAY CANPOLAT D,Şimşek S,rıhtım t,koker M,Yilmaz I Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. . 2023; 25 - 31. 10.14744/etd.2022.80633
Vancouver	dogruel f,GÜNAY CANPOLAT D,Şimşek S,rıhtım t,koker M,Yilmaz I Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. . 2023; 25 - 31. 10.14744/etd.2022.80633
IEEE	dogruel f,GÜNAY CANPOLAT D,Şimşek S,rıhtım t,koker M,Yilmaz I "Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium." , ss.25 - 31, 2023. 10.14744/etd.2022.80633
ISNAD	dogruel, fatma vd. "Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium". (2023), 25-31. https://doi.org/10.14744/etd.2022.80633

APA	dogruel f, GÜNAY CANPOLAT D, Şimşek S, rıhtım t, koker M, Yilmaz I (2023). Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. Erciyes Medical Journal, 45(1), 25 - 31. 10.14744/etd.2022.80633
Chicago	dogruel fatma,GÜNAY CANPOLAT DILEK,Şimşek Sevil,rıhtım tuğba,koker Mustafa Yavuz,Yilmaz Insu Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. Erciyes Medical Journal 45, no.1 (2023): 25 - 31. 10.14744/etd.2022.80633
MLA	dogruel fatma,GÜNAY CANPOLAT DILEK,Şimşek Sevil,rıhtım tuğba,koker Mustafa Yavuz,Yilmaz Insu Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. Erciyes Medical Journal, vol.45, no.1, 2023, ss.25 - 31. 10.14744/etd.2022.80633
AMA	dogruel f,GÜNAY CANPOLAT D,Şimşek S,rıhtım t,koker M,Yilmaz I Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. Erciyes Medical Journal. 2023; 45(1): 25 - 31. 10.14744/etd.2022.80633
Vancouver	dogruel f,GÜNAY CANPOLAT D,Şimşek S,rıhtım t,koker M,Yilmaz I Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium. Erciyes Medical Journal. 2023; 45(1): 25 - 31. 10.14744/etd.2022.80633
IEEE	dogruel f,GÜNAY CANPOLAT D,Şimşek S,rıhtım t,koker M,Yilmaz I "Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium." Erciyes Medical Journal, 45, ss.25 - 31, 2023. 10.14744/etd.2022.80633
ISNAD	dogruel, fatma vd. "Assessment of CD63 and CD203c Basophil Activation Tests in Patients with Immediate Drug Hypersensitivity Reaction to Rocuronium". Erciyes Medical Journal 45/1 (2023), 25-31. https://doi.org/10.14744/etd.2022.80633